Takeda Pharmaceutical Co. Ltd.
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 12, 2025), Takeda Pharmaceutical Co. Ltd. reported 11 stock positions worth $16.2 million. Its top holding was Hillevax (HLVX) at 60.2% of the portfolio, followed by Ovid Therapeutics (OVID, 14.5%) and Xilio Therapeutics (XLO, 6.6%). Its holdings were unchanged from Q4 2024.
- Most Recent 13F
- Q3 2025
- Location
- Tokyo, M0
- CIK
- 0001395064
- Portfolio Value
- $16.2M (Q1 2025)
- SEC Filing
- 0001395064-25-000055 ↗ filed May 12, 2025
Holdings Value
Holdings 11 stocks · $16.2M
| HLVX Hillevax Inc. | 60.21% | 6,724,000 | $9.8M | No change |
| OVID Ovid Therapeutics Inc. | 14.51% | 7,531,996 | $2.3M | No change |
| XLO Xilio Therapeutics Inc. | 6.59% | 1,475,121 | $1.1M | No change |
| EQ Equillium Inc. | 4.40% | 1,824,977 | $712K | No change |
| AMWL American Well Corp. Class A | 3.78% | 77,733 | $613K | No change |
| STTK Shattuck Labs Inc. | 3.02% | 515,619 | $490K | No change |
| LYEL Lyell Immunopharma Inc. | 2.74% | 823,317 | $443K | No change |
| TSBX Turnstone Biologics Corp. | 2.27% | 895,824 | $367K | No change |
| RANI Rani Therapeutics Holdings Class A | 1.58% | 203,190 | $256K | No change |
| THRD Third Harmonic Bio Inc. | 0.79% | 36,835 | $128K | No change |
| LAB Standard Biotools Inc. | 0.11% | 16,515 | $18K | No change |
Portfolio Sells Q4 2024 → Q1 2025
| None this quarter. | |||
Portfolio Buys Q4 2024 → Q1 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q3 2025 | 8 | $16.4M | OVID, EQ, XLO, STTK, LYEL |
| Q2 2025 | 11 | $19.6M | HLVX, OVID, XLO, AMWL, EQ |
| Q1 2025 | 11 | $16.2M | HLVX, OVID, XLO, EQ, AMWL |
| Q4 2024 | 11 | $26.6M | HLVX, OVID, XLO, EQ, STTK |
| Q3 2024 | 10 | $38.0M | HLVX, WVE, OVID, STTK, EQ |
| Q2 2024 | 13 | $232.3M | DNLI, HLVX, PHAT, WVE, OVID |
| Q1 2024 | 15 | $289.0M | HLVX, DNLI, PHAT, OVID, STTK |